Paget Disease of Bone (Osteitis Deformans) (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:Chronic skeletal disorder caused by disorganized bone remodeling—excessive bone resorption followed by chaotic bone formation—resulting in enlarged, deformed, and weak bone. Pathophysiology: Overactive osteoclasts → excessive bone breakdown. Compensatory osteoblastic activity → disorganized, sclerotic new bone (mosaic pattern). Affected bone is hypervascular, structurally weak, and prone to fractures. Commonly involves pelvis, skull, spine, femur, tibia. Etiology: Unknown; likely genetic (SQSTM1 mutations) or viral (paramyxovirus) triggers. Epidemiology: Onset usually after age 50, more common in men. Higher prevalence in European descent. Often asymptomatic, discovered incidentally via elevated alkaline phosphatase (ALP). 2. History Asymptomatic in up to 80%. Symptomatic findings: Bone pain (most common symptom; dull, aching, worse at night). Skeletal deformities: Skull enlargement (“increasing hat size”), frontal bossing. Bowing of long bones (femur, tibia). Hearing loss (CN VIII compression from skull involvement). Fractures: transverse (“chalk-stick”) fractures in long bones. Warmth over affected bone (due to increased vascularity). Complications: Osteoarthritis (bone deformity near joints). High-output heart failure (rare, from increased vascularity). Osteosarcoma (rare malignant transformation). Historical Clues: Older adult with bone pain + elevated ALP + normal calcium. Hearing loss or increasing hat size = classic clue. 3. Exam Findings General: Often normal; may show deformities or tenderness. Skull: Frontal bossing, craniofacial enlargement, hearing loss. Spine: Kyphosis or spinal stenosis (nerve compression). Extremities: Bowing of legs (anterolateral tibial curvature), increased warmth. CV: In advanced disease, signs of high-output cardiac failure. 4. Making the Diagnosis Laboratory Findings: Test Result Alkaline phosphatase (ALP) ↑↑ (high bone turnover) Calcium Normal Phosphate Normal PTH Normal Urinary hydroxyproline ↑ (bone collagen breakdown) Imaging: X-ray (diagnostic hallmark): Early: osteolytic (“blade of grass” or “flame-shaped”) lesions. Mixed phase: patchy sclerosis and cortical thickening. Late: dense, enlarged bone with deformity. Skull: “cotton wool” appearance. Bone scan: Increased uptake in affected bones—maps disease extent. Diagnostic Pattern: Elevated ALP with normal calcium and phosphate + characteristic radiologic findings. Gold Standard: X-ray evidence of mixed lytic–sclerotic lesions + elevated ALP. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or treatment regimens.) 1. Asymptomatic Patients: Observation if no pain or deformity and ALP stable. 2. Symptomatic or Active Disease: First-line: Bisphosphonates (e.g., alendronate, zoledronic acid) → inhibit osteoclasts. Second-line: Calcitonin (less potent, used if bisphosphonates contraindicated). Pain management: NSAIDs or acetaminophen for bone pain. Calcium and vitamin D supplementation to prevent hypocalcemia during treatment. 3. Complications Management: Orthopedic surgery: for fractures, severe deformity, or arthritis. Hearing aids for auditory loss. Monitor ALP levels for treatment response and recurrence.   QUESTION A 72-year-old man presents to his primary care clinic with a complaint of increasing right hip discomfort over the past few months. He denies recent trauma. His medical history includes hypertension and type 2 diabetes. He does not take corticosteroids. He reports difficulty hearing from his right ear and occasional headaches. Physical examination reveals mild anterior bowing of the right tibia and decreased range of motion in the right hip. Laboratory studies show: Serum calcium: 9.4 mg/dL (8.6–10.2) Phosphate: 3.1 mg/dL (2.5–4.5) Alkaline phosphatase: 430 U/L (40–129) PTH: 42 pg/mL (10–65) Which of the following is the most appropriate next step in management? A) Reassurance and observationB) Oral bisphosphonate therapyC) Serum 25-hydroxyvitamin D levelD) Total body bone scintigraphy  

Thyroid Cancer (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:Malignant tumors arising from thyroid follicular or parafollicular cells, varying from indolent to aggressive behavior. Epidemiology: Most common endocrine malignancy. Women > men; peak incidence 30–50 years. Excellent prognosis for differentiated cancers (papillary, follicular). Major Types (High-Yield): Type % Cell Origin Key Features Papillary carcinoma 80–85% Follicular cells Most common; lymphatic spread; prior radiation risk; excellent prognosis. Follicular carcinoma 10–15% Follicular cells Hematogenous spread (bone/lung); requires invasion for diagnosis. Medullary carcinoma 3–5% Parafollicular (C) cells Produces calcitonin; MEN 2A/2B association. Anaplastic carcinoma

Obesity (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:Obesity is a chronic, multifactorial condition characterized by excess adipose tissue leading to metabolic, mechanical, and cardiovascular complications. BMI 25–29.9 = overweight BMI ≥30 = obesity BMI ≥40 = severe obesity (class III) Pathophysiology: Energy imbalance: caloric intake > expenditure. Hormonal factors: Leptin resistance → impaired satiety. Insulin resistance → hyperinsulinemia and weight gain. Ghrelin ↑ → increased appetite. Genetic influences: MC4R mutations (common monogenic cause), polygenic risk. Environmental contributors: sedentary lifestyle, high-calorie diet, stress, sleep deprivation. Adipose tissue as an endocrine organ: Produces inflammatory cytokines → metabolic syndrome. Contributes to dyslipidemia, NAFLD, insulin resistance. Etiology: Behavioral/lifestyle factors High socioeconomic food access to calorie-dense foods Genetic predisposition Secondary causes (exam focus): Hypothyroidism Cushing syndrome Hypothalamic injury Medications: antipsychotics, insulin, sulfonylureas, steroids Epidemiology: Very common in the U.S.; affects all age groups. Strong correlation with cardiometabolic disease. 2. History Weight-related symptoms: Progressive weight gain, difficulty losing weight. Fatigue, joint pain (knees, back). Snoring or daytime somnolence (possible OSA). Metabolic symptoms: Polyuria/polydipsia (possible insulin resistance or T2DM). Dyspnea on exertion. Lifestyle clues: High caloric intake, low physical activity. Stress or sleep disorders affecting appetite regulation. Secondary cause clues: Cold intolerance, constipation (hypothyroidism). Striae, proximal weakness (Cushing syndrome). Hypothalamic injury history. 3. Exam Findings General: Elevated BMI, increased waist circumference (central adiposity). Cardiovascular: Hypertension, tachycardia. Respiratory: Signs of obstructive sleep apnea (large neck circumference). Dermatologic: Acanthosis nigricans (insulin resistance). Intertrigo or skin infections. Musculoskeletal: Joint tenderness, limited mobility. Endocrine clues: Violaceous striae or fat redistribution → possible Cushing syndrome. Thyroid enlargement or bradycardia → possible hypothyroidism. 4. Making the Diagnosis Primary Diagnosis: BMI-based classification on physical exam. Waist circumference: Men >40 in Women >35 in→ associated with ↑ cardiometabolic risk. Screening for Comorbidities (high-yield for exams): Blood pressure: screen for hypertension. Fasting glucose or HbA1c: evaluate for T2DM or insulin resistance. Lipid panel: detect dyslipidemia. Liver function tests: screen for NAFLD. TSH: rule out hypothyroidism. Sleep evaluation: for suspected OSA. Diagnostic Clues: Acanthosis nigricans → insulin resistance. Elevated ALT/AST → fatty liver progression. Gold Standard: Diagnosis is clinical based on BMI, supported by metabolic workup for comorbidities. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or treatment regimens.) 1. Lifestyle Intervention (First-Line) Calorie reduction tailored to nutritional needs. Increased physical activity (aerobic + resistance). Behavioral modification: goal setting, sleep optimization, stress management. 2. Pharmacologic Therapy (Conceptual) Indicated for BMI ≥30 or ≥27 with comorbidities. Mechanisms include appetite suppression, increased satiety, or reduced absorption (no dosing specifics). 3. Bariatric/Metabolic Surgery For BMI ≥40 or ≥35 with comorbidities (T2DM, severe OSA, NAFLD). Produces the largest and most durable weight reduction. Exam clue: resolves or improves T2DM rapidly post-op. 4. Comorbidity Management Treat hypertension, diabetes, dyslipidemia, NAFLD. Screen and treat sleep apnea. Monitor cardiovascular risk factors. Question A 43-year-old woman presents for evaluation of weight gain. She has a BMI of 37 kg/m² and reports daytime fatigue and loud snoring. Physical exam shows a large neck circumference and acanthosis nigricans. Labs reveal elevated fasting insulin and mildly elevated ALT. Which of the following complications is most strongly suggested by these findings? A. HyperthyroidismB. Obstructive sleep apneaC. Addison diseaseD. Primary hyperaldosteronism

SIADH — Syndrome of Inappropriate Antidiuretic Hormone Secretion (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:SIADH is characterized by excess ADH secretion → water retention, dilutional hyponatremia, and concentrated urine, occurring despite normal volume status and normal renal function. Pathophysiology: Excess ADH → ↑ renal water reabsorption → ↓ serum osmolality → hyponatremia. Body responds with natriuresis to maintain near-normal volume → euvolemic hyponatremia. Urine becomes inappropriately concentrated relative to serum. Etiology: CNS disorders: stroke, hemorrhage, trauma, infections, tumors. Pulmonary diseases: pneumonia, tuberculosis, small-cell lung cancer (ectopic ADH). Medications: SSRIs, carbamazepine, cyclophosphamide, oxytocin, NSAIDs. Malignancy: especially small-cell lung carcinoma (classic exam clue). Postoperative state: transient ADH secretion. Idiopathic in older adults. Epidemiology: Common cause of euvolemic hyponatremia, especially in hospitalized patients. 2. History Symptoms depend on severity and rate of sodium drop: Mild/moderate hyponatremia: nausea, headache, lethargy, confusion. Severe/acute hyponatremia: vomiting, somnolence, seizures, coma. Chronic SIADH: subtle cognitive changes, gait instability, falls. Historical clues: Recent CNS event or lung disease. Use of SSRIs, carbamazepine, or antipsychotics. Known or suspected small-cell lung cancer. 3. Exam Findings Volume status: EUVOLEMIC (key exam point). No edema No dry mucous membranes Normal skin turgor Neurologic: variable confusion, agitation, seizures if severe. Respiratory: findings related to underlying lung disease if present. General: normal BP and HR unless comorbidity present. 4. Making the Diagnosis Characteristic Laboratory Pattern: Measure SIADH Finding Serum sodium ↓ hyponatremia Serum osmolality ↓ (100 mOsm/kg) Urine sodium ↑ (>40 mEq/L) Volume status Euvolemic BUN/creatinine Low-normal Uric acid Low Diagnostic Steps: Confirm hypotonic hyponatremia (low serum Na and low serum osmolality). Assess volume status → euvolemia suggests SIADH. Check urine studies: concentrated urine + high urine sodium. Exclude other causes: Hypothyroidism (TSH) Adrenal insufficiency (cortisol/ACTH) Renal failure Gold Standard: Euvolemic hypotonic hyponatremia with inappropriately concentrated urine in absence of adrenal, thyroid, renal disease, or diuretics. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or treatment regimens.) 1. Treat Underlying Cause Stop causative medication (SSRI, carbamazepine). Treat lung infection or remove tumor if possible. 2. Fluid Management Fluid restriction = cornerstone for chronic SIADH. Salt tablets or increased dietary solute may help raise sodium. Hypertonic saline used in severe symptomatic hyponatremia (conceptual). 3. Medications (Conceptual) ADH antagonists (vaptans) for resistant cases. Loop diuretics with salt supplementation to enhance free water clearance. 4. Monitoring Avoid overly rapid sodium correction to prevent osmotic demyelination syndrome (exam favorite). Frequent monitoring of serum sodium.   QUESTION A 72-year-old man is admitted to the hospital with worsening confusion and lethargy over the past two days. He has a history of chronic obstructive pulmonary disease (COPD) and was recently diagnosed with small cell lung cancer. He takes inhaled bronchodilators and has no history of diuretic use. On examination, he appears euvolemic. There is no peripheral edema or signs of dehydration. Laboratory results are as follows: Serum sodium: 122 mEq/L (135–145) Serum osmolality: 258 mOsm/kg (275–295) Urine sodium: 48 mEq/L Urine osmolality: 620 mOsm/kg BUN: 6 mg/dL (7–20) Creatinine: 0.7 mg/dL (0.6–1.3) Which of the following is the most appropriate initial treatment? A) Hypertonic (3%) saline infusionB) Fluid restrictionC) Intravenous normal salineD) Oral sodium chloride tablets  

Diabetic Ketoacidosis (DKA) (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition: Acute, life-threatening metabolic complication of diabetes mellitus characterized by: Hyperglycemia Ketosis Anion gap metabolic acidosis Pathophysiology: Absolute or relative insulin deficiency + increased counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone). Promotes lipolysis → free fatty acids → ketone body production (β-hydroxybutyrate, acetoacetate). Leads to osmotic diuresis, dehydration, and electrolyte loss. Epidemiology: More common in Type 1 diabetes, but can occur in Type 2 diabetes under stress. Precipitating Factors: Infection (most common) Missed insulin doses Myocardial infarction, stroke, pancreatitis, trauma, or surgery Certain medications (e.g., glucocorticoids, SGLT2 inhibitors) 2. History Rapid onset (hours to days). Classic symptoms: Polyuria, polydipsia, dehydration. Nausea, vomiting, abdominal pain. Shortness of breath (Kussmaul respirations). Fatigue, confusion, fruity (acetone) breath. Historical clues: Recent illness, skipped insulin, new-onset Type 1 diabetes. History of poor glycemic control or insulin pump malfunction. 3. Exam Findings Vital Signs: Tachycardia, tachypnea, hypotension, fever (if infectious trigger). General: Dehydration: dry mucous membranes, poor skin turgor. Kussmaul respirations: deep, labored breathing due to metabolic acidosis. Fruity odor on breath (acetone). Neurologic: Lethargy, confusion, possible coma in severe cases. Abdominal: Tenderness and pain common due to acidosis (may mimic acute abdomen). 4. Making the Diagnosis Diagnostic Triad: Hyperglycemia: Glucose typically >250 mg/dL Metabolic acidosis: Arterial pH 600), minimal ketones, no significant acidosis. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or real-world directives.) Immediate priorities: Restore intravascular volume (IV fluids are first step). Correct electrolyte abnormalities (especially potassium). Administer insulin to suppress ketogenesis and correct acidosis. Identify and treat precipitating cause (infection, missed insulin, etc.). Monitoring: Hourly glucose checks. Frequent electrolytes (especially potassium and bicarbonate). Watch for cerebral edema, especially in children. Transition to long-term care: Once anion gap closes and patient can tolerate PO intake, transition to subcutaneous insulin. Complications to Recognize: Hypokalemia after insulin therapy. Cerebral edema (more common in pediatric DKA). ARDS or shock in severe dehydration QUESTION A 17-year-old girl with type 1 diabetes presents with nausea, vomiting, and rapid breathing. She reports missing several insulin doses. Physical exam reveals tachycardia, dry mucous membranes, and deep, labored respirations. Laboratory results show glucose 440 mg/dL, bicarbonate 12 mEq/L, and positive serum ketones. Which of the following best explains her acid-base disturbance? A. Lactic acid accumulation from hypoxiaB. Ketone body production due to insulin deficiencyC. Bicarbonate loss from vomitingD. Increased CO₂ retention due to respiratory depression  

Osteoporosis & Osteopenia (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition: Osteoporosis: Systemic skeletal disorder with low bone mass and microarchitectural deterioration, leading to fragility fractures. Osteopenia: Mild reduction in bone density (precursor to osteoporosis). Pathophysiology: Bone resorption > bone formation → loss of trabecular and cortical bone. Estrogen deficiency (postmenopause) and aging are key mechanisms. Leads to decreased bone strength without affecting mineralization. Diagnostic Criteria (DEXA T-scores): Category T-score Normal ≥ –1.0 Osteopenia –1.0 to –2.5 Osteoporosis ≤ –2.5 Severe (established) ≤ –2.5 + fragility fracture Epidemiology: Common in postmenopausal women and elderly men. Major cause of hip, vertebral, and wrist fractures in adults >50 years. Risk Factors: Non-modifiable: advanced age, female sex, white/Asian race, family history, early menopause. Modifiable: low BMI, smoking, alcohol, inactivity, low calcium/vitamin D intake. Secondary causes: glucocorticoids, hyperthyroidism, Cushing syndrome, hypogonadism, malabsorption, CKD, anticonvulsants. 2. History Often asymptomatic until fracture occurs. Typical Manifestations: Vertebral compression fractures → height loss, kyphosis (“dowager’s hump”), back pain. Hip or wrist fractures after minimal trauma. Chronic pain and functional decline. Historical Clues: Menopause, long-term steroid therapy, or secondary endocrine disease. 3. Exam Findings Spine: Kyphosis, height loss, tenderness over vertebrae. Gait: Unsteady, limited mobility post-fracture. Extremities: No deformity unless fracture present. Other systems: Usually normal labs and general appearance. 4. Making the Diagnosis Gold Standard: Dual-energy X-ray absorptiometry (DEXA) Measure at lumbar spine and hip; sometimes forearm if others unreliable. Typical Laboratory Findings (Primary Disease): Calcium, phosphate, ALP, PTH, vitamin D — all normal. Abnormal results suggest secondary osteoporosis (e.g., hyperparathyroidism, osteomalacia). Additional Evaluation: Screening: Women ≥65 years, or

Which of the following symptoms is most commonly associated with a tension pneumothorax?

A 51-year-old woman had an incisional cholecystectomy 6 hours ago. The nurse will place the highest priority on assisting the patient to

Continuing care of Mr. Thompson The nurse recognizes which laboratory findings are most concerning for ongoing bleeding?

To prepare a 56-year-old male patient with ascites for paracentesis, the nurse